{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:03:33Z","timestamp":1791389013613,"version":"4.3.3"},"reference-count":60,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.cmi.2019.01.017","type":"journal-article","created":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T23:31:26Z","timestamp":1550100686000},"page":"1364-1369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":102,"title":["Revisiting systemic treatment of bacterial endophthalmitis: a review of intravitreal penetration of systemic antibiotics"],"prefix":"10.1016","volume":"25","author":[{"given":"L.","family":"Brockhaus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Goldblum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Eggenschwiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Zimmerli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Marzolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2019.01.017_bib1","series-title":"ESCRS guidelines for prevention and treatment of endophthalmitis following cataract surgery: data, dilemmas and conclusions","author":"Barry","year":"2013"},{"key":"10.1016\/j.cmi.2019.01.017_bib2","first-page":"33","article-title":"Endogenous endophthalmitis: diagnosis and treatment","volume":"6","author":"Birnbaum","year":"2016","journal-title":"EyeNet Mag"},{"key":"10.1016\/j.cmi.2019.01.017_bib3","first-page":"5","article-title":"Recent advances in endophthalmitis management","volume":"2","author":"Wakely","year":"2014","journal-title":"R Coll Ophthalmol Focus"},{"key":"10.1016\/j.cmi.2019.01.017_bib4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/OPTH.S6461","article-title":"Endophthalmitis\u202f: pathogenesis, clinical presentation, management, and perspectives","volume":"4","author":"Kernt","year":"2010","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.cmi.2019.01.017_bib5","first-page":"1","article-title":"Post-surgical versus post-intravitreal injection endophthalmitis: changing patterns in causative flora","volume":"jul","author":"Ong","year":"2018","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.cmi.2019.01.017_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0002-9394(14)71959-2","article-title":"Spectrum and susceptibilities of microbiologic isolates in the endophthalmitis vitrectomy study","volume":"122","author":"Han","year":"1996","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.cmi.2019.01.017_bib7","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.ophtha.2014.02.001","article-title":"Microbiological spectrum and antibiotic sensitivity in endophthalmitis: a 25-year review","volume":"121","author":"Gentile","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.cmi.2019.01.017_bib8","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/j.jcrs.2016.11.008","article-title":"Antibiotic susceptibility of bacterial pathogens isolated from the aqueous and vitreous humor in the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study","volume":"42","author":"Asbell","year":"2016","journal-title":"J\u00a0Cataract Refract Surg"},{"key":"10.1016\/j.cmi.2019.01.017_bib9","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.ajo.2007.12.026","article-title":"Endophthalmitis caused by Bacillus species","volume":"145","author":"Miller","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.cmi.2019.01.017_bib10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jcrs.2012.10.037","article-title":"Six-year incidence of endophthalmitis after catarcat surgery: Swedish national study","volume":"39","author":"Friling","year":"2013","journal-title":"J\u00a0Cataract Refract Surg"},{"key":"10.1016\/j.cmi.2019.01.017_bib11","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1001\/archopht.1995.01100120009001","article-title":"Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis","volume":"113","year":"1995","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.cmi.2019.01.017_bib12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1055\/s-0029-1245219","article-title":"Combined meropenem and linezolid as a systemic treatment for postoperative endophthalmitis","volume":"227","author":"Tappeiner","year":"2010","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"10.1016\/j.cmi.2019.01.017_bib13","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1755-3768.2011.02365.x","article-title":"Adjunctive antibiotics in the treatment of acute bacterial endophthalmitis following cataract surgery","volume":"90","author":"Hooper","year":"2012","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.cmi.2019.01.017_bib14","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1055\/s-2008-1027512","article-title":"Current therapy for postoperative endophthalmitis","volume":"225","author":"Behrens-Baumann","year":"2008","journal-title":"Klin Monatsbl f\u00fcr Augenheilk"},{"key":"10.1016\/j.cmi.2019.01.017_bib15","series-title":"Leitlinie zur Prophylaxe und Therapie von Endophthalmitiden","year":"2005"},{"key":"10.1016\/j.cmi.2019.01.017_bib16","first-page":"502","article-title":"Cefazolin levels after intravitreal injection. Effects of inflammation and surgery","volume":"31","author":"Ficker","year":"1990","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.cmi.2019.01.017_bib17","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","article-title":"Progress in retinal and eye research pharmacokinetic: aspects of retinal drug delivery","volume":"57","author":"Del Amo","year":"2017","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.cmi.2019.01.017_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics10020066","article-title":"Review of introcular pharmakokinetics of anti-infectives commonly used in the treatment of infectious endophthalmitis","volume":"10","author":"Luaces-Rodr\u00edguez","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.cmi.2019.01.017_bib19","first-page":"1","article-title":"Pharmacokinetics of intravitreal antibiotics in endophthalmitis","volume":"4","author":"Radhika","year":"2014","journal-title":"J\u00a0Ophthalmic Inflamm Infect"},{"key":"10.1016\/j.cmi.2019.01.017_bib21","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0002-9394(14)72784-9","article-title":"Vancomycin levels in the vitreous cavity after intravenous administration","volume":"119","author":"Meredith","year":"1995","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.cmi.2019.01.017_bib22","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1128\/CMR.00007-10","article-title":"Penetration of drugs through the blood\u2013cerebrospinal fluid\/blood\u2013brain barrier for treatment of central nervous system infections","volume":"23","author":"Nau","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2019.01.017_bib23","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1755-3768.1978.tb03817.x","article-title":"Ampicillin penetration into the rabbit eye","volume":"56","author":"Salminen","year":"1878","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.cmi.2019.01.017_bib24","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/0002-9394(76)90548-1","article-title":"Intraocular penetration of amoxicillin","volume":"82","author":"Faigenbaum","year":"1976","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.cmi.2019.01.017_bib25","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/00006982-199806000-00006","article-title":"Penetration of piperacillin into the vitreous after intravenous administration","volume":"18","author":"Robinet","year":"1998","journal-title":"Retina"},{"key":"10.1016\/j.cmi.2019.01.017_bib26","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/archopht.1990.01070050109043","article-title":"Vitreous cefazolin levels after intravenous injection","volume":"108","author":"Martin","year":"1990","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.cmi.2019.01.017_bib27","first-page":"2179","article-title":"The intravitreal penetration of ceftriaxone in man following systemic administration","volume":"30","author":"Sharir","year":"1989","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.cmi.2019.01.017_bib28","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1128\/AAC.22.4.622","article-title":"Pharmacokinetics and cerebrospinal fluid bactericidal activity of ceftriaxone in the treatment of pediatric patients with bacterial meningitis","volume":"22","author":"Del Rio","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.01.017_bib29","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/00006982-199515020-00012","article-title":"Vitreous cavity penetration of ceftazidime after intravenous administration","volume":"15","author":"Aguilar","year":"1995","journal-title":"Retina"},{"key":"10.1016\/j.cmi.2019.01.017_bib30","first-page":"63","article-title":"Penetration of ceftazidime into the normal rabbit and human eye","volume":"44","author":"Walstad","year":"1985","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.cmi.2019.01.017_bib31","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000063838","article-title":"Intravitreal penetration of cefepime after systemic administration to humans","volume":"216","author":"Aras","year":"2002","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.cmi.2019.01.017_bib32","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/112067219400400207","article-title":"Human vitreous penetration of imipenem","volume":"4","author":"Adenis","year":"1994","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.cmi.2019.01.017_bib33","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/0002-9394(87)90180-2","article-title":"Penetration of imipenem into human aqueous and vitreous humor","volume":"104","author":"Axelrod","year":"1987","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.cmi.2019.01.017_bib34","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1089\/jop.1999.15.439","article-title":"Penetration and decay of meropenem into the human aqueous humor and vitreous","volume":"15","author":"Schauersberger","year":"1999","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.cmi.2019.01.017_bib35","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/BF02764289","article-title":"Intraocular penetration of rifampin after oral administration","volume":"228","author":"Wong","year":"1990","journal-title":"Graefe\u2019s Arch Exp Ophthalmol"},{"key":"10.1016\/j.cmi.2019.01.017_bib36","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1128\/AAC.36.7.1575","article-title":"Intraocular penetration of rifampin in humans","volume":"36","author":"Outman","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.01.017_bib37","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.ophtha.2003.09.042","article-title":"Aqueous and vitreous penetration of linezolid after oral administration","volume":"111","author":"Fiscella","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.cmi.2019.01.017_bib38","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1089\/jop.2010.0022","article-title":"Aqueous and vitreous penetration of linezolid and levofloxacin after oral administration","volume":"26","author":"George","year":"2010","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.cmi.2019.01.017_bib39","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/jac\/dkn516","article-title":"Pharmacokinetics of linezolid in human non-inflamed vitreous after systemic administration","volume":"63","author":"Horcajada","year":"2009","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.01.017_bib40","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/00006982-200507000-00013","article-title":"Human vitreous distribution of linezolid after a single oral dose","volume":"25","author":"Ciulla","year":"2005","journal-title":"Retina"},{"key":"10.1016\/j.cmi.2019.01.017_bib41","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.2147\/TCRM.S109444","article-title":"Safety of long-term use of linezolid\u202f: results of an open-label study","volume":"12","author":"Vazquez","year":"2016","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.cmi.2019.01.017_bib42","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1592\/phco.30.12.1247","article-title":"Presence of adequate intravitreal concentration of daptomycin after systemic intravenous administration in an patient with endogenous endophthalmitis","volume":"30","author":"Sheridan","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cmi.2019.01.017_bib43","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0002-9394(14)70487-8","article-title":"Aminoglycoside levels in the rabbit vitreous cavity after intravenous administration","volume":"122","author":"El-Massry","year":"1996","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.cmi.2019.01.017_bib44","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1128\/AAC.44.6.1674-1679.2000","article-title":"Pharmacokinetics of ciprofloxacin in the human eye: a clinical study and population pharmacokinetic analysis","volume":"44","author":"Morlet","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.01.017_bib45","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/eye.1999.137","article-title":"Human aqueous and vitreous humour levels of ciprofloxacin following oral and topical administration","volume":"13","author":"Cekic","year":"1999","journal-title":"Eye"},{"key":"10.1016\/j.cmi.2019.01.017_bib46","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0161-6420(92)31943-8","article-title":"Intravitreal penetration of oral ciprofloxacin in humans","volume":"99","author":"El Baba","year":"1992","journal-title":"Ophthalmology"},{"key":"10.1016\/j.cmi.2019.01.017_bib47","first-page":"2388","article-title":"The intravitreal penetration of orally administered ciprofloxacin in humans","volume":"32","author":"Keren","year":"1991","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.cmi.2019.01.017_bib48","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/jac\/26.1.99","article-title":"Penetration of ciprofloxacin into the aqueous humour of the uninflamed human eye after oral administration","volume":"26","author":"Sweeney","year":"1990","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.01.017_bib49","first-page":"724","article-title":"Intraocular penetration of ciprofloxacin after infusion and oral administration","volume":"36","author":"Mounier","year":"1988","journal-title":"Pathol Biol"},{"key":"10.1016\/j.cmi.2019.01.017_bib50","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1006\/exer.1996.0101","article-title":"Aqueous and vitreous penetration of ciprofloxacin following different modes of systemic administration","volume":"63","author":"Madu","year":"1996","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.cmi.2019.01.017_bib51","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/S0161-6420(99)90527-4","article-title":"Aqueous and vitreous penetration of levofloxacin after oral administration","volume":"106","author":"Fiscella","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.cmi.2019.01.017_bib52","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/bjo.86.4.387","article-title":"Vitreous penetration of levofloxacin in the uninflamed phakic human eye","volume":"86","author":"Herbert","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.cmi.2019.01.017_bib53","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1001\/archopht.124.2.178","article-title":"Vitreous and aqueous penetration of orally administered moxifloxacin in humans","volume":"124","author":"Hariprasad","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.cmi.2019.01.017_bib54","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ajo.2006.09.023","article-title":"Vitreal penetration of oral and topical moxifloxacin in humans","volume":"143","author":"Fuller","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.cmi.2019.01.017_bib55","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/IAE.0b013e31814fb0ed","article-title":"Vitreal penetration of oral moxifloxacin in humans","volume":"28","author":"Lott","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.cmi.2019.01.017_bib56","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/sj.eye.6702094","article-title":"Vitreous and aqueous penetration of orally administered moxifloxacin in humans","volume":"20","author":"Vedantham","year":"2006","journal-title":"Eye"},{"key":"10.1016\/j.cmi.2019.01.017_bib57","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1086\/605576","article-title":"Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis","volume":"49","author":"Alffenaar","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.01.017_bib58","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(12)70264-5","article-title":"Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial","volume":"13","author":"Ruslami","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2019.01.017_bib59","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1097\/ICO.0b013e318298ddf8","article-title":"Vitreous and aqueous penetration of orally administered trimethoprim-sulfamethoxazole combination in humans","volume":"2","author":"Feiz","year":"2013","journal-title":"Cornea"},{"key":"10.1016\/j.cmi.2019.01.017_bib60","doi-asserted-by":"crossref","first-page":"24","DOI":"10.5694\/j.1326-5377.1981.tb132050.x","article-title":"High-dose co-trimoxazole and its penetration through uninflamed meninges","volume":"2","author":"Goodwin","year":"1981","journal-title":"Med J Aust"},{"key":"10.1016\/j.cmi.2019.01.017_bib61","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1089\/jop.1998.14.575","article-title":"Ocular penetration of oral clarithromycin in humans","volume":"14","author":"Al-Sibai","year":"1998","journal-title":"J\u00a0Ocul Pharmacol Ther"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X19300394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X19300394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:24:09Z","timestamp":1761117849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X19300394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":60,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S1198743X19300394"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2019.01.017","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revisiting systemic treatment of bacterial endophthalmitis: a review of intravitreal penetration of systemic antibiotics","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2019.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}